Anecdotal reports have suggested that the use of 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) is a prodigious problem across the United States. Unfortunately, no longitudinal evidence exists to support this contention. In the current study, data from the Drug Abuse Warning Network (DAWN), Monitoring the Future (MTF), and National Household Survey on Drug Abuse (NHSDA) are used to explore ecstasy use trends in the United States during the 1990s. While the use of ecstasy has increased over time, its prevalence is significantly less than other drugs of abuse. These findings suggest that anecdotal reports of an ecstasy epidemic is premature and that a less frenzied approach to ecstasy control and education may be warranted.
Get full access to this article
View all access options for this article.
References
1.
ShulginA., History of MDMA, in Ecstasy: The Clinical, Pharmacological and Neurotoxic Effects of the Drug MDMA, PeroutkaS. J. (ed.), Kluwar Academic Publishers, Norwell, Massachusetts, pp. 1–20, 1990.
2.
GreerG. R. and TolbertR., A Method of Conducting Therapeutic Sessions with NDMA, Journal of Psychoactive Drugs, 30: 4, pp. 371–379, 1998.
3.
PeroutkaS. J., Incidence of Recreational Use of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) on an Undergraduate Campus, New England Journal of Medicine, 317: 24, pp. 1542–1543, 1987.
4.
RandolphW. F., International Drug Scheduling: Convention on Psychotropic Substances, Stimulant and/or Hallucinogenic Drugs, Federal Register, 49: 140, pp. 29273–29274, 1984.
5.
MullenF. M., Schedules of Controlled Substances: Proposed Placement of 3,4-methylenedioxymethamphetamine into Schedule I, Federal Register, 49: 146, pp. 30210–30211, 1984.
6.
RicaurteG. A.BryanG.StraussL.SeldenL., and SchusterC., Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals, Science, 229, pp. 986–988, 1985.
7.
GrinspoonL. and BakalarJ. B., Can Drugs Be Used to Enhance the Psychotherapeutic Process?American Journal of Psychotherapy, 40: 3, pp. 393–403, 1986.
8.
HolstenD. W. and SchieserD. W., Controls Over the Manufacture of MDMA, Journal of Psychoactive Drugs, 18: 4, pp. 371–372, 1986.
9.
LawnJ. C., Schedules of Controlled Substances: Temporary Placement of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule 1, Federal Register, 50: 105, pp. 23118–23120, 1985.
10.
LawnJ. C., Schedules of Controlled Substances: Scheduling of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule 1 of the Controlled Substances Act, Federal Register, 51: 198, pp. 36552–36560, 1988.
11.
McCannU. D.RidenourA.ShamanY., and RicaurteG. A., Serotonin Neurotoxicity after 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”): A Controlled Study, Neuropsychopharmacology, 10: 2, pp. 129–138, 1994.
12.
RicaurteG. A.McCannU. D.SzaboZ., and ScheffelU., Toxicodynamics and Long-Term Toxicity of the Recreational Drug, 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), Toxicology Letters, 112–113, pp. 143–146, 2000.
13.
CloudJ., 2000, June 5, The Lure of Ecstasy, Time, 155: 23, p. 10.
14.
National Broadcasting Company (NBC), Inc., Dateline NBC, National Broadcasting Company, Inc., New York, 2000.
15.
BuffumJ. and MoserC., MDMA and Sexual Function, Journal of Psychoactive Drugs, 18: 4, pp. 355–359, 1986.
16.
CuomoM. J. and DymentP. G., Increasing Use of ‘Ecstasy’ (MDMA) and Other Hallucinogens on a College Campus, Journal of American College Health, 42: 6, pp. 271–274, 1994.
17.
KlitzmanR. L.PopeH. G., and HudsonJ. I., MDMA (“Ecstasy”) Abuse and High-Risk Sexual Behaviors among 169 Gay and Bisexual Men, American Journal of Psychiatry, 157, pp. 1162–1664, 2000.
18.
KunsmanG. W.LevineB.KuhlmanJ. J.JonesR. L.HughesR. O.FujiyamaC. I., and SmithM. L., MDA-MDMA Concentrations in Urine Specimens, Journal of Analytical Toxicology, 20, pp. 517–521, 1996.
19.
MeilmanP. W.GaylorM. S.TurcoJ. H., and StoneJ. E., Drug Use among College Undergraduates: Current Use and 10-Year Trends, The International Journal of the Addictions, 25: 9, pp. 389–395, 1990.
20.
SiegelR. K., MDMA Nonmedical Use and Intoxication, Journal of Psychoactive Drugs, 18: 4, pp. 349–354, 1986.
21.
YacoublanG., Correlates of Ecstasy Use among 10th Graders Surveyed Through Monitoring the Future, Journal of Psychoactive Drugs, 34: 2, pp. 209–213, 2002.
22.
YacoubianG.ArriaA.FostE., and WishE. D., Estimating the Prevalence of Ecstasy Use among Juvenile Offenders, Journal of Psychoactive Drugs, 34: 2, pp. 225–230, 2002.
23.
Substance Abuse and Mental Health Services Administration, Year-End 2000 Emergency Department Data from the Drug Abuse Warning Network, U.S. Department of Health and Human Services, Rockville, Maryland, 2001.
24.
Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network Annual Medical Examiner Data 1999, U.S. Department of Health and Human Services, Rockville, Maryland, 2000.
25.
JohnstonL. D.O'MalleyP. M., and BachmanJ. G., National Survey Results on Drug Use from the Monitoring the Future Study, 1975–1999 (Volume 1), U.S. Department of Health and Human Services, Rockville, Maryland, 2000.
26.
Substance Abuse and Mental Health Services Administration, Summary of Findings from the 1999 National Household Survey on Drug Abuse, U.S. Department of Health and Human Services, Rockville, Maryland, 2000.
27.
National Institute of Justice, 1999 Arrestee Drug Abuse Monitoring (ADAM) Annual Report, U.S. Department of Justice, Washington, D.C., 2000.
28.
YacoubianG., Ecstasy Surveillance in the United States: The Time to Monitor Juvenile Arrestees Has Arrived, Journal of Offender Monitoring, 14, pp. 23–24, 2001.
29.
YacoubianG., Assessing ADAM's Domain: Past, Present, and Future, Contemporary Drug Problems, 27, pp. 121–135, 2000.
30.
WishE. D., The Crack Epidemic of the 1980's and the Birth of a New Drug Monitoring System in the United States, paper presented at the conference on “The Crack Decade: Research Perspectives and Lessons Learned,” National Institute of Justice and the National Institute on Drug Abuse, Baltimore, Maryland, 1997.
31.
DupontR. L. and WishE. D., Operation Tripwire Revisited, The Annals of the American Academy of Political and Social Science, 521, pp. 91–111, 1992.
32.
WishE. D.HoffmanJ. A., and NemesS., The Validity of Self-Reports of Drug Use at Treatment Admission and at Follow-Up: Comparisons with Urinalysis and Hair Assays, in The Validity of Self-Reported Drug Use: Improving the Accuracy of Survey Estimates, HarrisonL. and HughesA. (eds.), National Institute of Drug Abuse, Rockville, Maryland, 1997.
33.
YacoubianG., Reassessing the Need for Urinalysis as a Validation Technique, Journal of Drug Issues, 30: 2, pp. 323–334, 2000.
